forsyth

Bernie took pharmaceutical companies money

'Rig the system': Alarm sounded as Trump backtracks on major promise
Trump's order, titled "Lowering Drug Prices by Once Again Putting Americans First," instructs Health and Human Services Secretary Robert F. Kennedy Jr. to work with Congress to "modify" the Medicare drug price negotiation program that was established under the Biden administration and has already yielded significant results despite pharma companies' best efforts to block it in court.

U.S. President Donald Trump on Tuesday signed an executive order that aims to delay Medicare negotiations for a broad category of prescription drugs, handing the deep-pocketed pharmaceutical industry a major win as it lobbies aggressively against efforts to rein in its pricing power.

Specifically, Trump calls for a four-year extension of the period during which small-molecule prescription drugs are exempt from price negotiations with Medicare. Under the Inflation Reduction Act, small-molecule drugs-which are typically taken in pill form and represent 90% of medications currently in circulation-are not subject to the price negotiation process until at least nine years after their Food and Drug Administration approval date.

"Extending negotiation delay periods," Knievel added, "is nothing but a total capitulation to the demands of drug corporation lobbyists that want to continue to overcharge Medicare beneficiaries and taxpayers."

The advocacy group Protect Our Care said following the order that "Trump just caved to Big Pharma-again."

"His new executive order pushes to delay Medicare drug price negotiations, giving drug companies four extra years to price gouge seniors," said Protect Our Care. "The only winners here are the drug companies."